RNAseq analysis of B16 tumors confirmed that the expression of Hist2h3c1, a predominant AURKB target, was significantly reduced following both i.p. (FC = 0.13, p = 0.017) and i.t. (FC = 0.047, p < 0.0001) AZD1152 treatment compared to vehicle treatment, indicating that the drug was appropriately targeting AURKB in the tumor microenvironment. This evidence concerns the gene AURKB and neoplasm.